ULK1 and neoplasm: Decreased expression of Beclin1 along with a reduced level of LC3-II as well as a relative decline in ULK1 and TFEB1 mRNA levels resulted in enhanced chemotherapy, mitigated drug resistance, and tumor growth inhibition on the cisplatin-resistant tumor in xenograft mouse model [7].